In September, multiple biotech companies announced significant layoffs, with Inventprise cutting 7% of its workforce, bluebird bio reducing 25%, and Athira Pharma laying off 70% after a failed trial. Other notable reductions included Charles River Laboratories (3%), Cidara Therapeutics (30%), and Astellas Gene Therapies impacting around 100 employees. The trend reflects ongoing challenges in the biotech sector, with companies restructuring to focus on core projects and manage costs.
